Literature DB >> 16862157

Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody.

Micah A Luftig1, Marco Mattu, Paolo Di Giovine, Romas Geleziunas, Renee Hrin, Gaetano Barbato, Elisabetta Bianchi, Michael D Miller, Antonello Pessi, Andrea Carfí.   

Abstract

Elicitation of potent and broadly neutralizing antibodies is an important goal in designing an effective human immunodeficiency virus-1 (HIV-1) vaccine. The HIV-1 gp41 inner-core trimer represents a functionally and structurally conserved target for therapeutics. Here we report the 2.0-A-resolution crystal structure of the complex between the antigen-binding fragment of D5, an HIV-1 cross-neutralizing antibody, and 5-helix, a gp41 inner-core mimetic. Both binding and neutralization depend on residues in the D5 CDR H2 loop protruding into the conserved gp41 hydrophobic pocket, as well as a large pocket in D5 surrounding core gp41 residues. Kinetic analysis of D5 mutants with perturbed D5-gp41 interactions suggests that D5 persistence at the fusion intermediate is crucial for neutralization. Thus, our data validate the gp41 N-peptide trimer fusion intermediate as a target for neutralizing antibodies and provide a template for identification of more potent and broadly neutralizing molecules.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16862157     DOI: 10.1038/nsmb1127

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  78 in total

1.  Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

Authors:  Miroslaw K Gorny; Ruimin Pan; Constance Williams; Xiao-Hong Wang; Barbara Volsky; Timothy O'Neal; Brett Spurrier; Jared M Sampson; Liuzhe Li; Michael S Seaman; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  Virology       Date:  2012-03-07       Impact factor: 3.616

Review 2.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

3.  Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.

Authors:  Elisabetta Bianchi; Joseph G Joyce; Michael D Miller; Adam C Finnefrock; Xiaoping Liang; Marco Finotto; Paolo Ingallinella; Philip McKenna; Michael Citron; Elizabeth Ottinger; Robert W Hepler; Renee Hrin; Deborah Nahas; Chengwei Wu; David Montefiori; John W Shiver; Antonello Pessi; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-18       Impact factor: 11.205

4.  Small molecule mimetics of an HIV-1 gp41 fusion intermediate as vaccine leads.

Authors:  Michael J Caulfield; Vadim Y Dudkin; Elizabeth A Ottinger; Krista L Getty; Paul D Zuck; Robin M Kaufhold; Robert W Hepler; Georgia B McGaughey; Michael Citron; Renee C Hrin; Ying-Jie Wang; Michael D Miller; Joseph G Joyce
Journal:  J Biol Chem       Date:  2010-10-13       Impact factor: 5.157

5.  Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency.

Authors:  John J Dwyer; Karen L Wilson; Kimberly Martin; Jennifer E Seedorff; Aisha Hasan; Robyn J Medinas; Donna K Davison; Michael D Feese; Hans-Thomas Richter; Hidong Kim; Thomas J Matthews; Mary K Delmedico
Journal:  Protein Sci       Date:  2008-04       Impact factor: 6.725

6.  Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.

Authors:  Paolo Ingallinella; Elisabetta Bianchi; Neal A Ladwa; Ying-Jie Wang; Renee Hrin; Maria Veneziano; Fabio Bonelli; Thomas J Ketas; John P Moore; Michael D Miller; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

7.  Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.

Authors:  Kelly Champagne; Akira Shishido; Michael J Root
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

8.  Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.

Authors:  Elena Gustchina; Carole A Bewley; G Marius Clore
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

9.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

Review 10.  HIV-1 and influenza antibodies: seeing antigens in new ways.

Authors:  Peter D Kwong; Ian A Wilson
Journal:  Nat Immunol       Date:  2009-06       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.